Literature DB >> 4256008

Mithramycin treatment of hypercalcaemia and renal failure in a patient with paratesticular embryonic sarcoma.

V Parsons, G Scott, M Baum, E Molland, J Makin.   

Abstract

A 17-year-old patient with a small paratesticular embryonic sarcoma presented with symptoms of renal failure, polyuria and widespread bone metastases. Investigation revealed hypercalcaemia and uraemia without any evidence of hyperparathyroidism. The hypercalcaemia responded over a period of weeks to administration of mithramycin with initial improvement in the symptoms and metabolic derangements. Control was lost with the necrosis of intra-abdominal tumour deposits and haemorrhagic polypoid deposits in the alimentary tract. The value and hazards of mithramycin are well demonstrated by these rare complications of this type of tumour.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4256008      PMCID: PMC2008444          DOI: 10.1038/bjc.1971.39

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS.

Authors:  J H BROWN; B J KENNEDY
Journal:  N Engl J Med       Date:  1965-01-21       Impact factor: 91.245

2.  Rhabdomyosarcoma: clinical and pathological features and comparison with human fetal and embryonal skeletal muscle.

Authors:  R B PATTON; R C HORN
Journal:  Surgery       Date:  1962-10       Impact factor: 3.982

3.  Specific effect of mithramycin on embryonal carcinoma of the testis.

Authors:  B J Kennedy; W O Griffen; P Lober
Journal:  Cancer       Date:  1965-12       Impact factor: 6.860

4.  Mithramycin therapy in disseminated germinal testicular cancer.

Authors:  N W Ream; C P Perlia; J Wolter; S G Taylor
Journal:  JAMA       Date:  1968-06-17       Impact factor: 56.272

5.  Mithramycin treatment of malignant hypercalcaemia.

Authors:  C R Edwards; G M Besser
Journal:  Br Med J       Date:  1968-07-20

6.  Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma.

Authors:  F R Singer; R M Neer; T M Murray; H T Keutmann; L J Deftos; J T Potts
Journal:  N Engl J Med       Date:  1970-09-17       Impact factor: 91.245

7.  Mithramycin inhibition of ribonucleic acid synthesis.

Authors:  J W Yarbro; B J Kennedy; C P Barnum
Journal:  Cancer Res       Date:  1966-01       Impact factor: 12.701

8.  Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.

Authors:  V Parsons; M Baum; M Self
Journal:  Br Med J       Date:  1967-02-25

9.  Production of parathyroid hormone by nonparthyroid tumors.

Authors:  L M Sherwood; J L O'Riordan; G D Aurbach; J T Potts
Journal:  J Clin Endocrinol Metab       Date:  1967-01       Impact factor: 5.958

  9 in total
  1 in total

1.  Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer.

Authors:  Shan Wang; Collin Gilbreath; Rahul K Kollipara; Rajni Sonavane; Xiaofang Huo; Paul Yenerall; Amit Das; Shihong Ma; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2020-05-30       Impact factor: 8.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.